Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
iTeos Therapeutics, Inc. (ITOS) is a clinical-stage biopharmaceutical company that has focused on immuno-oncology, developing therapies designed to counteract immunosuppressive pathways in the tumor microenvironment. Company communications describe programs targeting the TIGIT/CD226 axis, the adenosine pathway, ENT1, TREM2, and PTPN1/2, with candidates such as belrestotug, EOS-984, EOS-215, and inupadenant.
The news flow around iTeos has included clinical trial updates, collaboration decisions, strategic reviews, and corporate transactions. For example, the company has reported interim data from Phase 2 and Phase 3 studies in first-line non-small cell lung cancer and head and neck squamous cell carcinoma, including the GALAXIES Lung-201, GALAXIES Lung-301, GALAXIES H&N-202, and TIG-006 trials. In May 2025, iTeos and its partner GSK decided to terminate the belrestotug development program after interim analyses did not meet predefined criteria for progression-free survival and response rate improvements compared with monotherapy.
News items have also covered early-stage pipeline progress, such as Phase 1 development of EOS-984, IND-enabling and early clinical work for EOS-215, and preclinical data on a PTPN1/2 inhibitor. The company has presented data at major scientific and medical meetings, including the American Association for Cancer Research Annual Meeting and the ESMO Immuno-Oncology Congress, highlighting translational and preclinical findings on its candidates and pathway signatures.
In 2025, iTeos announced a strategic shift, stating its intention to wind down operations and focus on maximizing shareholder value through its cash position and potential asset sales. Subsequent news detailed an agreement for iTeos to be acquired by Concentra Biosciences through a tender offer and merger, followed by delisting from Nasdaq and deregistration of its common stock. This news page provides a record of these developments, allowing investors, researchers, and other readers to review the company’s clinical, scientific, and corporate milestones over time.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced a $120 million Registered Direct Offering led by existing investors RA Capital Management and Boxer Capital. The purchase price of $17.50 per share represents a premium of approximately 44% to the last close. This offering strengthens the company's balance sheet, increasing the pro forma cash position to $715 million, extending anticipated runway through 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
